Genotype-guided dosing algorithm for warfarin

BEHAVIORAL2 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), The Third Xiangya Hospital of Central South University

Conditions

Atrial FibrillationAtrial FlutterDeep Venous ThrombosisStrokeVenous Thrombosis

Phase 3

Clarification of Optimal Anticoagulation Through Genetics

CompletedNCT00839657

National Heart, Lung, and Blood Institute (NHLBI)Atrial Fibrillation, Atrial Flutter, Stroke +1

Start: 2009-09-30End: 2013-11-30Updated: 2016-04-20

Unknown Phase

Genotype-guided Warfarin Individualized Treatment

CompletedNCT02211326

The Third Xiangya Hospital of Central South UniversityAtrial Fibrillation, Deep Venous Thrombosis

Start: 2014-09-01End: 2017-05-01Updated: 2017-11-06

Related Papers

Long Short-Term Memory Network for Development and Simulation of Warfarin Dosing Model Based on Time Series Anticoagulant Data

Frontiers in Cardiovascular Medicine2022-05-117 citations

Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial.

2021-01-066 citations

Genotype-Guided Dosing of Warfarin in Chinese Adults

Circulation Genomic and Precision Medicine2020-06-0821 citations

A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics

PLoS ONE2016-01-0836 citations

A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing

New England Journal of Medicine2013-11-19742 citations

Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.

2013-07-1211 citations

Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

2010-11-1774 citations